Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 23 | 2025 | 408 | 6.290 |
Why?
|
| Tuberculosis | 25 | 2025 | 553 | 5.880 |
Why?
|
| Tuberculosis, Pulmonary | 10 | 2025 | 228 | 3.190 |
Why?
|
| DNA Methylation | 5 | 2025 | 1146 | 1.810 |
Why?
|
| Immune Tolerance | 4 | 2024 | 158 | 1.790 |
Why?
|
| Feces | 6 | 2025 | 788 | 1.500 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2024 | 176 | 1.360 |
Why?
|
| Adaptive Immunity | 3 | 2021 | 96 | 1.300 |
Why?
|
| Epigenesis, Genetic | 5 | 2025 | 772 | 1.290 |
Why?
|
| Sputum | 9 | 2025 | 116 | 1.250 |
Why?
|
| BCG Vaccine | 5 | 2023 | 111 | 1.140 |
Why?
|
| HIV Infections | 12 | 2025 | 2074 | 0.980 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2025 | 545 | 0.910 |
Why?
|
| Citric Acid Cycle | 1 | 2024 | 49 | 0.900 |
Why?
|
| Lipopolysaccharides | 2 | 2025 | 319 | 0.840 |
Why?
|
| Antitubercular Agents | 8 | 2024 | 265 | 0.820 |
Why?
|
| Interferon-gamma Release Tests | 3 | 2025 | 84 | 0.800 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 31 | 0.790 |
Why?
|
| Fetal Blood | 1 | 2023 | 178 | 0.780 |
Why?
|
| Sensitivity and Specificity | 14 | 2025 | 2171 | 0.730 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 114 | 0.640 |
Why?
|
| Bacteriological Techniques | 2 | 2016 | 90 | 0.620 |
Why?
|
| Leukocytes | 1 | 2020 | 223 | 0.610 |
Why?
|
| Communicable Diseases | 1 | 2021 | 164 | 0.610 |
Why?
|
| Ascaris lumbricoides | 1 | 2018 | 19 | 0.590 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 18 | 0.580 |
Why?
|
| Schistosomiasis | 1 | 2018 | 54 | 0.570 |
Why?
|
| Ascariasis | 1 | 2018 | 73 | 0.550 |
Why?
|
| Immunity, Innate | 2 | 2021 | 417 | 0.540 |
Why?
|
| Th1 Cells | 1 | 2018 | 159 | 0.540 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 507 | 0.530 |
Why?
|
| Transcriptome | 2 | 2022 | 1137 | 0.510 |
Why?
|
| Schistosoma | 1 | 2016 | 13 | 0.510 |
Why?
|
| Immunologic Factors | 2 | 2021 | 184 | 0.500 |
Why?
|
| Humans | 52 | 2025 | 134085 | 0.480 |
Why?
|
| Antigens, Helminth | 1 | 2016 | 188 | 0.460 |
Why?
|
| Population Surveillance | 2 | 2022 | 419 | 0.450 |
Why?
|
| Macrophages | 1 | 2016 | 710 | 0.360 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2666 | 0.350 |
Why?
|
| Signal Transduction | 2 | 2021 | 4934 | 0.350 |
Why?
|
| Immunologic Memory | 2 | 2021 | 199 | 0.310 |
Why?
|
| Child | 17 | 2025 | 25843 | 0.300 |
Why?
|
| DNA, Bacterial | 3 | 2024 | 500 | 0.270 |
Why?
|
| Interleukin-4 | 2 | 2018 | 148 | 0.260 |
Why?
|
| Animals | 9 | 2024 | 36543 | 0.260 |
Why?
|
| South Africa | 2 | 2023 | 127 | 0.250 |
Why?
|
| Child, Preschool | 9 | 2025 | 14838 | 0.240 |
Why?
|
| Cytokines | 3 | 2022 | 1400 | 0.240 |
Why?
|
| Adolescent | 12 | 2025 | 20601 | 0.230 |
Why?
|
| Succinates | 1 | 2024 | 20 | 0.230 |
Why?
|
| Succinic Acid | 1 | 2024 | 15 | 0.230 |
Why?
|
| Interferon-gamma | 2 | 2018 | 538 | 0.230 |
Why?
|
| Everolimus | 1 | 2024 | 51 | 0.220 |
Why?
|
| T-Lymphocytes | 2 | 2025 | 1814 | 0.220 |
Why?
|
| Inflammation | 2 | 2022 | 1594 | 0.220 |
Why?
|
| Gene Silencing | 1 | 2025 | 247 | 0.220 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 384 | 0.220 |
Why?
|
| Biomarkers | 2 | 2024 | 3433 | 0.220 |
Why?
|
| Adult | 15 | 2025 | 31964 | 0.210 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2025 | 160 | 0.200 |
Why?
|
| Immunity | 1 | 2023 | 186 | 0.200 |
Why?
|
| Young Adult | 6 | 2025 | 9917 | 0.200 |
Why?
|
| Ultraviolet Therapy | 1 | 2022 | 2 | 0.200 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 20 | 0.190 |
Why?
|
| Prospective Studies | 8 | 2025 | 6602 | 0.190 |
Why?
|
| Isosporiasis | 1 | 2021 | 3 | 0.190 |
Why?
|
| Guinea Pigs | 1 | 2022 | 171 | 0.190 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 306 | 0.190 |
Why?
|
| CRISPR-Cas Systems | 1 | 2025 | 296 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 58 | 0.180 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 72 | 0.180 |
Why?
|
| Cryptococcus | 1 | 2021 | 3 | 0.180 |
Why?
|
| Herpesvirus 8, Human | 1 | 2021 | 52 | 0.180 |
Why?
|
| Systems Biology | 1 | 2021 | 63 | 0.180 |
Why?
|
| Cryptococcosis | 1 | 2021 | 44 | 0.170 |
Why?
|
| Kava | 1 | 2020 | 8 | 0.170 |
Why?
|
| Allergy and Immunology | 1 | 2021 | 29 | 0.170 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2021 | 76 | 0.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 69 | 0.170 |
Why?
|
| Vaccination | 2 | 2023 | 1015 | 0.170 |
Why?
|
| History, 19th Century | 1 | 2021 | 120 | 0.170 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2021 | 124 | 0.170 |
Why?
|
| Mozambique | 3 | 2025 | 23 | 0.170 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2023 | 958 | 0.170 |
Why?
|
| Eosinophilia | 1 | 2021 | 105 | 0.170 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2021 | 275 | 0.170 |
Why?
|
| Cellular Senescence | 1 | 2022 | 201 | 0.170 |
Why?
|
| Sarcoma, Kaposi | 1 | 2021 | 137 | 0.170 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 38 | 0.160 |
Why?
|
| Herpesviridae Infections | 1 | 2021 | 147 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 259 | 0.160 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 74 | 0.160 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 346 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 245 | 0.160 |
Why?
|
| Case-Control Studies | 2 | 2025 | 3665 | 0.160 |
Why?
|
| Diarrhea | 1 | 2021 | 342 | 0.160 |
Why?
|
| Transcription Factors | 2 | 2021 | 2729 | 0.160 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 391 | 0.160 |
Why?
|
| History, 20th Century | 1 | 2021 | 396 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 266 | 0.150 |
Why?
|
| RNA | 1 | 2022 | 606 | 0.150 |
Why?
|
| Immunization | 1 | 2020 | 315 | 0.150 |
Why?
|
| Gene Expression | 1 | 2023 | 1621 | 0.150 |
Why?
|
| Health Personnel | 1 | 2023 | 541 | 0.150 |
Why?
|
| Uganda | 3 | 2025 | 89 | 0.150 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 69 | 0.140 |
Why?
|
| Colony Count, Microbial | 1 | 2018 | 89 | 0.140 |
Why?
|
| Limit of Detection | 1 | 2018 | 77 | 0.140 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2018 | 34 | 0.140 |
Why?
|
| Mycobacterium chelonae | 1 | 2017 | 4 | 0.140 |
Why?
|
| Autoantibodies | 1 | 2021 | 467 | 0.140 |
Why?
|
| Male | 15 | 2025 | 66057 | 0.140 |
Why?
|
| Wound Healing | 1 | 2021 | 488 | 0.140 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2017 | 44 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2020 | 356 | 0.130 |
Why?
|
| Skin | 2 | 2017 | 553 | 0.130 |
Why?
|
| Viral Vaccines | 1 | 2020 | 345 | 0.130 |
Why?
|
| Helminths | 1 | 2017 | 47 | 0.130 |
Why?
|
| Female | 14 | 2025 | 71851 | 0.130 |
Why?
|
| Tanzania | 3 | 2024 | 73 | 0.130 |
Why?
|
| Age Factors | 1 | 2023 | 2997 | 0.130 |
Why?
|
| Calibration | 1 | 2016 | 100 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 306 | 0.130 |
Why?
|
| CD56 Antigen | 1 | 2016 | 28 | 0.130 |
Why?
|
| Phagosomes | 1 | 2016 | 38 | 0.130 |
Why?
|
| Hookworm Infections | 1 | 2017 | 123 | 0.120 |
Why?
|
| Dermoscopy | 1 | 2015 | 3 | 0.120 |
Why?
|
| CD3 Complex | 1 | 2016 | 93 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 753 | 0.120 |
Why?
|
| Reference Standards | 1 | 2016 | 247 | 0.120 |
Why?
|
| Intravital Microscopy | 1 | 2015 | 19 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 194 | 0.120 |
Why?
|
| Immunophenotyping | 1 | 2016 | 342 | 0.120 |
Why?
|
| Coinfection | 1 | 2017 | 182 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 3043 | 0.110 |
Why?
|
| Age of Onset | 1 | 2016 | 637 | 0.110 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2015 | 73 | 0.110 |
Why?
|
| Latent Tuberculosis | 1 | 2016 | 76 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2021 | 5206 | 0.110 |
Why?
|
| Interleukin-10 | 1 | 2016 | 191 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 358 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 385 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 396 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 112 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 649 | 0.110 |
Why?
|
| Lysosomes | 1 | 2016 | 264 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 366 | 0.110 |
Why?
|
| Antigens, Bacterial | 1 | 2016 | 320 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2016 | 837 | 0.110 |
Why?
|
| Risk Factors | 2 | 2020 | 11166 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 451 | 0.100 |
Why?
|
| Africa South of the Sahara | 2 | 2025 | 129 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1190 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3186 | 0.090 |
Why?
|
| Pathology, Molecular | 2 | 2022 | 65 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2025 | 239 | 0.090 |
Why?
|
| Infant | 6 | 2025 | 13201 | 0.090 |
Why?
|
| Middle Aged | 7 | 2025 | 29402 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2301 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2561 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1854 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4806 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 907 | 0.070 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2007 | 18 | 0.070 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2007 | 57 | 0.070 |
Why?
|
| Mice | 1 | 2024 | 19044 | 0.070 |
Why?
|
| Prognosis | 1 | 2016 | 5085 | 0.060 |
Why?
|
| Geriatric Psychiatry | 1 | 2006 | 12 | 0.060 |
Why?
|
| Foreign Medical Graduates | 1 | 2006 | 12 | 0.060 |
Why?
|
| Time Factors | 1 | 2016 | 6604 | 0.060 |
Why?
|
| Aged | 2 | 2023 | 21756 | 0.060 |
Why?
|
| Family Practice | 1 | 2006 | 92 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2573 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2025 | 48 | 0.060 |
Why?
|
| Jurkat Cells | 1 | 2025 | 95 | 0.060 |
Why?
|
| Tuberculin Test | 1 | 2025 | 123 | 0.060 |
Why?
|
| HIV-1 | 1 | 2007 | 488 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 293 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 1978 | 0.050 |
Why?
|
| Gene Editing | 1 | 2025 | 213 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 72 | 0.050 |
Why?
|
| Kenya | 1 | 2022 | 63 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2025 | 822 | 0.050 |
Why?
|
| Phototherapy | 1 | 2022 | 39 | 0.050 |
Why?
|
| Isospora | 1 | 2021 | 3 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2006 | 484 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 45 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2017 | 272 | 0.050 |
Why?
|
| HIV | 1 | 2023 | 195 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 150 | 0.050 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2022 | 73 | 0.050 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2021 | 20 | 0.040 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 18 | 0.040 |
Why?
|
| Isoniazid | 1 | 2021 | 67 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 256 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 198 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2022 | 13051 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2021 | 138 | 0.040 |
Why?
|
| Rituximab | 1 | 2021 | 165 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2021 | 303 | 0.040 |
Why?
|
| Cell Line | 1 | 2025 | 2858 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2006 | 803 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1157 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 382 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 277 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1488 | 0.040 |
Why?
|
| United States | 3 | 2022 | 11750 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2021 | 310 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2019 | 91 | 0.040 |
Why?
|
| Syndrome | 1 | 2021 | 1159 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1199 | 0.030 |
Why?
|
| Metabolomics | 1 | 2021 | 458 | 0.030 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2017 | 55 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1681 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2017 | 131 | 0.030 |
Why?
|
| Photometry | 1 | 2015 | 4 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2021 | 824 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2006 | 1250 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 723 | 0.030 |
Why?
|
| Phenotype | 1 | 2025 | 4556 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2017 | 325 | 0.030 |
Why?
|
| Rural Population | 1 | 2017 | 280 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1303 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 2043 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1575 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1669 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2023 | 17518 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2006 | 187 | 0.010 |
Why?
|
| Data Collection | 1 | 2006 | 399 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8607 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2006 | 1062 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 3999 | 0.010 |
Why?
|